IQVIA
IQV | NYSE
$264.73
-$0.39 (-0.15%)
At close: Nov 16, 2026, 4:00 PM ET
$264.73
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 6:44 PM ET
IQVIA Company Profile
Company profile explainedCompany Profile
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Key Executives
| Name | Position |
|---|---|
| Ari Bousbib | Chief Executive Officer & Chairman |
| Michael J. Fedock | Executive Vice President & Chief Financial Officer |
| Alistair Grenfell | President of Commercial Solutions |
| Duane Sachs | Senior Vice President of Corporate Development |
| Eric Sherbet | Executive Vice President, General Counsel & Secretary |
| James G. Berkshire | Executive Vice President of Global Infrastructure & Operations |
| Jeffrey A. Spaeder | Chief Medical & Scientific Officer |
| Keriann Cherofsky | Senior Vice President, Corporate Controller & Chief Accounting Officer |
| Kerri Joseph | Senior VP of Investor Relations & Treasurer |
| Trudy Stein | Chief Human Resources Officer & Executive Vice President |
| W. Richard Staub | President of Research & Development Solutions |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | 10-Q | Quarterly Report |
| Oct 27, 2026 | 8-K | Current Report |
| Sep 23, 2026 | 8-K | Current Report |
| Sep 09, 2026 | 8-K | Current Report |
| Sep 04, 2026 | 4 | Filing |
| Aug 04, 2026 | 4 | Filing |
| Aug 04, 2026 | 4 | Filing |
| Aug 03, 2026 | 144 | Filing |
| Jul 31, 2026 | 144 | Filing |
| Jul 31, 2026 | 4 | Filing |
IQVIA
| Country | United States |
| IPO Date | May 9, 2013 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 94,000 |
| CEO | Ari Bousbib |
Contact Details
2400 Ellis Road Durham,
North Carolina 27703 United States
Stock Details
| Ticker Symbol | IQV |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001478242 |
| CUSIP Number | 46266C105 |
| ISIN Number | US46266C1053 |
| SIC Code | 8731 |
Recent News
- 3 days ago / zacks.comIQVIA Stock Jumps 59% in 6 Months: Here's What You Should Know
- 7 days ago / fool.comIQVIA: 3 Key Takeaways for Long-Term Investors
- 20 days ago / marketbeat.comWhat IQVIA (IQV) Said on Its Q3 Earnings Call
- 21 days ago / zacks.comIQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/Y
- 21 days ago / zacks.comIQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue Estimates
- 26 days ago / zacks.comIQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should Know
- 28 days ago / seekingalpha.comIQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires Execution
- 28 days ago / zacks.comIQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
- 1 month ago / zacks.comHere's Why IQVIA Holdings (IQV) is a Strong Momentum Stock
- 2 months ago / zacks.comExtensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity
Add to Watchlist
Select watchlists to add or remove IQV